NEWS

We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A...

We're delighted to announce that the Milner Therapeutics Institute will play an active role at BioTrinity 2026 next month, with both a dedicated...

On 22 January, we were delighted to host the Cambridge–Oxford BioVenture Showcase, bringing together innovators, early‑stage founders, researchers,...

Last week, the Milner Institute welcomed more than 45 of its affiliated companies to a business-to-business networking event on the Cambridge...

We’re delighted that our Executive Director, Professor Cathy Tralau-Stewart, has continued her thought leadership work with Drug Discovery World,...

We are thrilled to announce that the Functional Genomics Screening Laboratory (FGSL) has been awarded an OBN Award in the Most Impactful Industry...

Milner Executive Director Cathy Tralau-Stewart was delighted to join Drug Discovery World (DDW) at their 2025 Symposium this month, which brought...

Earlier this week, we were delighted to team up with Cambridge Network to host an event at the West Hub in Cambridge. The event provided an overview...

The Milner Institute was proud to take part in BioCentury’s Grand Rounds Europe conference in Cambridge this month. Over three days of keynotes,...

We are delighted to announce that Daiichi Sankyo has joined the Milner Therapeutics Consortium as our tenth pharma partner. The Milner team works...

Last week, we were delighted to welcome Pippa Heylings MP, Charlotte Cane MP and Councillor Olaf Hauk to the Milner Therapeutics Institute. The...

We are delighted to share that Dr Namshik Han, Head of AI and Computational Research at the Milner Therapeutics Institute, has begun a new role as...

We are delighted to share that the Milner Therapeutics Institute has been announced as a finalist for a 2025 OBN Award in the category of Most...

Last week, we were proud to host our 2025 Pitch Day, bringing together a vibrant mix of biotech innovators, investors, and translational science...

This week, the Milner Therapeutics Institute hosted its annual Symposium – a hybrid event welcoming approximately 500 in-person delegates and 250+...

We are excited for several Milner events taking place across Cambridge next week, including our annual Therapeutics Symposium and Pitch Day. The...

Shift Bioscience, a company based in the Milner Institute Bio-incubator, has published new research  identifying a novel, single-gene target for...

We were delighted to host a signing ceremony with Yonsei University last week, for a new Memorandum of Understanding (MOU) between our institute at...

We were delighted to welcome over 120 delegates in Cambridge last week, for a Cambridge-Google Workshop: Learning from Experts in Computational...

The Milner Institute was delighted to take part in two Cambridge Festival events again this year. Held each spring, the Festival features a mix of...

Last week, we were delighted to launch the new Functional Genomics Screening Laboratory (FGSL) here at the Milner Therapeutics Institute in...

We are delighted that the Milner Therapeutics Consortium has been renewed until 2029, which will continue to provide opportunities for our academic...

This week, Milner Institute Director Professor Sir Tony Kouzarides was pleased to attend a special event in celebration of Astex’s 25-year...

We are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance...

We are delighted that our Executive Director – Dr Cathy Tralau-Stewart – was invited to attend J.P. Morgan's 43rd Annual Healthcare Conference this...

Last week, 40 Milner Affiliates joined our inaugural B2B Matchmaking Event here in Cambridge, bringing together a diverse range of start-ups,...

We are delighted that the Milner Therapeutics Institute (MTI) has joined a three-year collaboration with the science funding agency ARIA and...

We're delighted to announce that the Medical Research Council (MRC), in collaboration with the Biotechnology and Biological Sciences Research...

Earlier this year, our Head of Research Dr Nicola McCarthy sat down with Megan Thomas, Multimedia Editor at Drug Discovery World, to explore...

Global life sciences leader and Milner affiliate Cytiva recently established a footprint in the Jeffrey Cheah Biomedical Centre on the Cambridge...

Last week, we were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together. On...

We were delighted to welcome Flagship Pioneering to the Milner Therapeutics Institute this week. Noubar Afeyan and colleagues from Flagship visited...

We are delighted to share that our Director, Professor Sir Tony Kouzarides – a Professor of Cancer Biology at the University of Cambridge and a...

We are delighted to announce that Chun Hao Wong has joined the Milner team as the MTI lead for the new MRC-AstraZeneca-University of Cambridge...

This year the Milner Institute was delighted to take part in the University of Cambridge’s interdisciplinary Cambridge Festival. The Festival takes...

The functional genomics screening laboratory (FGSL), a joint venture between our Institute at the University of Cambridge, the Medical Research...

We are delighted that our Head of Computational Biology and AI, Dr Namshik Han, was featured on Cytiva’s ‘Discovery Matters' podcast series last...

We are delighted to announce a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art...

We are delighted to share that the Pathania Lab join a team of researchers who have been awarded £1.5 million in The Brain Tumour Charity's Quest...

We are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month. Now with 14...

We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside...

We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad...

The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning...

We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate...

Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class...

This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the...